Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy
Guardado en:
Autores principales: | Massimo Girardis, Howard W Clark, Reena M Bhatt, Stefano Busani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3af4a199c42647cabb8e6aef1fba7edb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lung transplant after 6 months on ECMO support for SARS-CoV-2-induced ARDS complicated by severe antibody-mediated rejection
por: Johan Nilsson, et al.
Publicado: (2021) -
Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)
por: Seyed MohammadReza Hashemian, et al.
Publicado: (2021) -
RDS affected neonatal conditions and the health care situations in different health care settings
por: N. Deval, et al.
Publicado: (2016) -
A term neonate with cyanosis with crying
por: Matthew C. Pertzborn, et al.
Publicado: (2021) -
Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
por: N. A. Geppe, et al.
Publicado: (2021)